Scientists test drug combo to outsmart aggressive lung cancer
NCT ID NCT04695925
Summary
This study is testing if a targeted drug (osimertinib) works better alone or combined with two chemotherapy drugs for people with advanced non-small cell lung cancer who have two specific genetic changes (EGFR and TP53 mutations). It aims to see which approach better controls the cancer, helps people live longer, and maintains quality of life. The trial has enrolled 294 adults who have not yet received treatment for their advanced cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Central Hospital of Guangdong Nongken, Zhanjiang Cancer Hospital
Zhanjiang, China
-
Department of Medical Oncology,Cancer Center of Sun Yat-Sen University
Guangzhou, Guangdong, 510060, China
Conditions
Explore the condition pages connected to this study.